Futura Medical, the designer of an erection-maintaining condom, has seen its share price surge on rumours it is likely to receive the nod from European regulators.
Having already slumped from a year’s high of 50p to almost 12p, the shares have recently risen by 125% to current levels, after the company revealed it had 'received positive regulatory opinion relating to the pharmaceutical aspects of [the condom]’. This means that the long-awaited authorisation looks likely, and the condom, which will be sold under the Durex brand of prophylactic giant SSL, should have a huge market.
The launch of the product, which is expected in 2009 and is conditional on the regulatory green light, would totally transform the company’s fortunes. Presently burning around £2m of cash a year, revenues from a successful launch would allow Futura to develop its other products, which are based around similar technology and include a ‘his and hers’ product with stimulating gel inside and out.
Figures for the half-year to June showed Futura lost £1.1m before tax as it guided a product to treat premature ejaculation into Phase I trials and saw another to treat pain relief successfully complete its own equivalent test. The balance sheet in June recorded coffers containing £1.7m of cash, and new finance director Derek Martin can call on a further £1m cash facility from the bank.
Even at 27.5p, the shares are still trading at less than a third of their 89.5p three-year high, where they boast a considerable degree of speculative appeal.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
Market cap: £15.85m
PE Forecast: n/a
Share price: 27.50p
£7,277 That’s what you would have in your portfolio if you had invested £6,000 into the six Company Watch recommendations in our April 2009 issue.
Advertisement
Growth Company Investor, in association with the London Stock Exchange, presents the most wide-ranging and detailed examination of the AIM market: AIM in Review 2010. For more information and to order, click here or contact our marketing team on 020 7250 7056.
M&A on AIM 2009 is a unique and wide-ranging examination of merger and acquisition activity on AIM over the past 12 months, with an analysis of all the acquisitions, disposals, takeovers and delistings on AIM, including
canvassing the opinions of some of the major M&A powerbrokers. To order click here.
Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.
Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.
The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today and benefit from a £10 discount!
This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.
Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Energy industry consultant KBC performed resiliently in recession-hit 2009 and entered 2010 with a robust order book.
Organic composting specialist TEG is pursuing long-term contracts after turning £1.6m of annual losses into £155,000 pre-tax profits in calendar 2009.
European Goldfields hopes to move from AIM to the Full List by the end of 2010 after securing a key permit in Romania.